论文部分内容阅读
卵巢癌是妇科肿瘤中死亡率最高的一种.病人早期手术后,通常采用化疗或放疗。放射性标记的单克隆抗体可用于妇科肿瘤的治疗,如~(131)Ⅰ标记的单克隆抗体 OC125F(ab′)_2片断对卵巢癌细胞具有特异性,因此了解该抗体的药代动力学及其在体内分布的情况,对于临床应用,尤其是放疗应用很重要。静脉注射(iV)后,到达肿瘤组织的抗体量低,而在其它组织的量很高,为改善抗体在靶肿瘤的聚集,可将放射性标记的抗体皮下或直接注入体腔。本文研究卵巢癌病人 iv 或腹腔注射(ip)~(131)Ⅰ标记的单克隆抗体 OC125后体内的分布及药代动力学的情况。
Ovarian cancer is the highest mortality rate in gynecologic oncology, which is usually followed by chemotherapy or radiotherapy after early surgery. Radiolabeled monoclonal antibodies can be used in the treatment of gynecological tumors. For example, the ~ (131) Ⅰ labeled monoclonal antibody OC125F (ab ’) _ 2 is specific for ovarian cancer cells, and therefore its pharmacokinetics and its Distribution in the body, for clinical applications, especially radiotherapy applications is very important. After intravenous (iV), the amount of antibody reaching the tumor tissue is low and the amount is high in other tissues. To improve antibody aggregation in the target tumor, the radiolabeled antibody can be injected subcutaneously or directly into the body cavity. In this study, we investigated the distribution and pharmacokinetics of ovarian cancer patients iv or intraperitoneal (ip) ~ (131) Ⅰ labeled monoclonal antibody OC125.